Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Cancer Vaccines Begin to Take Center Stage With Investigators Anticipating an Even Brighter Future

April 30th 2025

Expert investigators discuss the current and future landscape of cancer vaccine development in various tumor types.

SYN818 Shows Favorable Safety Profile in Locally Advanced or Metastatic Solid Tumors

April 29th 2025

A phase 1b trial examining SYN818 plus olaparib in patients with solid tumors will be conducted in the second half of 2025.

Runimotamab Plus Trastuzumab Is Active and Tolerable in HER2+ Breast Cancer

April 29th 2025

Runimotamab in combination with trastuzumab led to clinical activity and tolerability vs runimotamab alone in HER2-positive breast cancer.

Sequencing Regorafenib After Fruquintinib Improves OS in mCRC

April 29th 2025

Initial fruquintinib followed by regorafenib extended OS vs the reverse sequence of the agents in patients with metastatic colorectal cancer.

Olaparib Plus Pembrolizumab Shows Efficacy in HRR Gene–Mutated Advanced Tumors With/Without HRD Positivity

April 27th 2025

Olaparib plus pembrolizumab was safe and effective in HRR gene–mutated and/or HRD-positive advanced tumors.

TARA-002 Showcases Early Clinical Activity in BCG-Naive and -Unresponsive High-Risk NMIBC

April 27th 2025

Interim data from a phase 2 study support the potential of TARA-002 as an intravesical immunotherapy in high-risk NMIBC.

Perioperative Pembrolizumab Poses a New Standard of Care Option in Resectable, Locally Advanced HNSCC

April 27th 2025

Perioperative pembrolizumab with postoperative radiation with or without cisplatin showed durable EFS in resectable, locally advanced HNSCC.

Nogapendekin Alfa Inbakicept Displays Efficacy in BCG-Unresponsive NMIBC

April 27th 2025

Nogapendekin alfa inbakicept demonstrated sustained CR rates in patients with high-risk BCG-unresponsive NMIBC.

Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab Displays Efficacy in Advanced Urothelial Carcinoma

April 26th 2025

Enfortumab vedotin plus pembrolizumab followed by surgery led to high CR rates in advanced urothelial cancer.

TAR-200 Produces Unprecedented CR Rates in BCG-Unresponsive, High-Risk NMIBC

April 26th 2025

TAR-200 showed promising results in treating patients with BCG-unresponsive, high-risk NMIBC, achieving an 82.4% complete response rate.

MRD Assessment Informs RFS Outcomes With Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC

April 26th 2025

Twelve-month RFS was associated with MRD status in patients with BCG-unresponsive, NMIBC who received treatment with cretostimogene grenadenorepvec.

Orelabrutinib Wins Approval in China for First-Line CLL and SLL

April 25th 2025

China’s NMPA has approved orelabrutinib for the first-line treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.

China’s NMPA Approves Toripalimab in First-Line Melanoma

April 25th 2025

China’s NMPA has approved the sNDA for toripalimab as a first-line treatment for patients with unresectable or metastatic melanoma.

Rina-S Displays Early Efficacy in Advanced Ovarian Cancer

April 25th 2025

Elizabeth K. Lee, MD, discusses data from the phase 1/2 RAINFOL-01 study of Rina-S in advanced ovarian cancer.

Extended Adjuvant Pyrotinib Shows Promising Efficacy After Trastuzumab-Based Therapy in HER2+ Breast Cancer

April 23rd 2025

Pyrotinib led to high 2-year iDFS rates in the adjuvant setting following adjuvant trastuzumab-based treatment in HER2-positive breast cancer.

PSMA PET Guides the Individualized Use of Lutetium-Based Therapies in mCRPC

April 22nd 2025

Evan Y. Yu, MD, discusses the clinical evolution of radiopharmaceuticals for patients with mCRPC and how PSMA PET may evolve to monitor treatment response.

Dr Garfall on the Rationale of the Phase 2 BMT CTN 1902 Trial in Myeloma

April 21st 2025

Alfred L. Garfall, MD, MS, discusses the rationale of the phase 2 BMT CTN 1902 trial in multiple myeloma.

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma

April 18th 2025

María-Victoria Mateos, MD, PhD, discusses data from the long-term update of CARTITUDE-4 she presented during the 51st Annual EBMT Meeting.

An EBMT Machine Learning Model Aids With Transplant Risk Stratification in Myelofibrosis

April 18th 2025

Juan Carlos Hernández-Boluda, MD, PhD, discusses the development of an EBMT machine learning model for predicting allo-HCT risk in myelofibrosis.

JAK Inhibitor Safety Is at the Heart of Treatment Selection in Myelofibrosis

April 17th 2025

Jamile M. Shammo, MD, discusses how the differences between the available JAK inhibitors in myelofibrosis guide her treatment considerations.